28项研究的荟萃分析表明:Stretta疗法能够持续显著地改善GERD症状

2017-03-01 佚名 Mederi Therapeutics

该全新研究结合上述经济数据表明,Stretta 获得了患者及医疗保险公司的支持,既能提升治疗水平,又能降低费用。

-这是一项里程碑式研究

Mederi Therapeutics 今天发布对28项研究的荟萃分析,而这些研究主要涉及2468名采用 Stretta 疗法来治疗胃食管反流病 (GERD) 的患者。该研究题为《Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease》(对内窥镜射频用于治疗胃食管反流病的对照与前瞻性群组疗效研究的系统评估与荟萃分析),刊登在Surgical Endoscopy》(外科内窥镜)上。研究报告的作者包括 Esophageal and Swallowing Center 负责人、Metro Health Medical Center(城市健康医疗中心)胃肠病学与肝脏病学主任和凯斯西储大学 (Case Western University) 教授 Ronnie Fass(医学博士),以及统计专家和 Biomedical Strategies 总裁 Frederick Cahn(博士)。

generated by system

研究报告主要作者 Ronnie Fass 博士表示:“这项全面分析结合了我们的临床专长和 Cahn 博士的统计经验,旨在对当前可用数据进行最为彻底而客观的评估。研究结果表明 Stretta 是有效安全的胃食管反流病临床疗法。”

Cahn 博士拥有超过30年的医疗经验,他在评论该研究的高标准时表示:“对这些研究的彻底分析遵循了 Cochrane 推荐方法学,表明其质量较高且存在的偏见风险较低。我们还发现 Stretta 疗法在一系列广泛研究中具有一致的良好疗效。这项荟萃分析的优势包括 -- 长达10年的随访(平均为25个月),大量的调查对象(2468人)和包含28项研究,这使其位列系统评估与荟萃分析的前1%。”

相关分析结果:

  • 显著改善与健康相关的生活质量
  • 显著减少胃灼热症状
  • 大部分患者不需服用质子泵抑制剂 (PPI)
  • 显著治愈糜烂性食管炎
  • 显著减少食管酸暴露
  • 不良事件发生率较低,不高于1%

Fass 博士对此解释说:“这项研究的结果表明 Stretta 疗法可以显著缓解胃食管反流病的各种症状,同时积极影响生理参数,例如减少酸暴露和治愈糜烂性食管炎。”

胃食管反流病是指胃内容物反流入食管,进而引起胃灼热和反流等症状的一种疾病。这种反流现象由于胃部与食管之间的屏障肌肉松弛而产生。胃食管反流病最为常见的疗法是服药,通常为质子泵抑制剂。然而,大约30%的患者认为其效果不好,其他患者则担心相关的长期风险。

Stretta 将低剂量射频 (RF) 能量作用于食管下端括约肌 (LES)。该疗法增加了括约肌的厚度,从而减少 LES 的组织顺应性和短暂松弛现象,改善胃部与食管之间的屏障功能,并且缓解胃食管反流病的各种症状。Stretta 是一种非手术内窥镜疗法,成为了替代抗反流手术、明显更加安全的微创疗法,并且无需长期服药。

近期发布的健康经济数据表明,相比于长期服药或手术,采用 Stretta 来治疗胃食管反流病可以为医疗保险公司节省大量费用。Fass 还表示:“我们的荟萃分析和这份经济数据结合在一起,为采用 Stretta 治疗胃食管反流病患者进一步提供了支持。”

Mederi 首席执行官 Bob Knarr 在解释这项研究的影响力时表示:“这项深入的数据分析肯定了 Stretta 在治疗胃食管反流病方面的安全性和有效性。该全新研究结合上述经济数据表明,Stretta 获得了患者及医疗保险公司的支持,既能提升治疗水平,又能降低费用。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836905, encodeId=ad68183690578, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 03 08:44:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681332, encodeId=b500168133287, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Oct 29 08:44:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021548, encodeId=3c3a202154835, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Sep 24 04:44:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913830, encodeId=b678191383002, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jul 12 10:44:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471841, encodeId=140414e184131, content=<a href='/topic/show?id=4ff9e967c4' target=_blank style='color:#2F92EE;'>#GERD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7967, encryptionId=4ff9e967c4, topicName=GERD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=929a7169504, createdName=mashirong, createdTime=Fri Mar 03 06:44:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836905, encodeId=ad68183690578, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 03 08:44:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681332, encodeId=b500168133287, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Oct 29 08:44:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021548, encodeId=3c3a202154835, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Sep 24 04:44:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913830, encodeId=b678191383002, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jul 12 10:44:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471841, encodeId=140414e184131, content=<a href='/topic/show?id=4ff9e967c4' target=_blank style='color:#2F92EE;'>#GERD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7967, encryptionId=4ff9e967c4, topicName=GERD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=929a7169504, createdName=mashirong, createdTime=Fri Mar 03 06:44:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
    2017-10-29 venlin
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836905, encodeId=ad68183690578, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 03 08:44:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681332, encodeId=b500168133287, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Oct 29 08:44:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021548, encodeId=3c3a202154835, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Sep 24 04:44:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913830, encodeId=b678191383002, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jul 12 10:44:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471841, encodeId=140414e184131, content=<a href='/topic/show?id=4ff9e967c4' target=_blank style='color:#2F92EE;'>#GERD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7967, encryptionId=4ff9e967c4, topicName=GERD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=929a7169504, createdName=mashirong, createdTime=Fri Mar 03 06:44:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1836905, encodeId=ad68183690578, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 03 08:44:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681332, encodeId=b500168133287, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Oct 29 08:44:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021548, encodeId=3c3a202154835, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Sep 24 04:44:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913830, encodeId=b678191383002, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jul 12 10:44:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471841, encodeId=140414e184131, content=<a href='/topic/show?id=4ff9e967c4' target=_blank style='color:#2F92EE;'>#GERD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7967, encryptionId=4ff9e967c4, topicName=GERD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=929a7169504, createdName=mashirong, createdTime=Fri Mar 03 06:44:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
    2017-07-12 ysjykql
  5. [GetPortalCommentsPageByObjectIdResponse(id=1836905, encodeId=ad68183690578, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 03 08:44:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681332, encodeId=b500168133287, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Oct 29 08:44:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021548, encodeId=3c3a202154835, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Sep 24 04:44:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913830, encodeId=b678191383002, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jul 12 10:44:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471841, encodeId=140414e184131, content=<a href='/topic/show?id=4ff9e967c4' target=_blank style='color:#2F92EE;'>#GERD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7967, encryptionId=4ff9e967c4, topicName=GERD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=929a7169504, createdName=mashirong, createdTime=Fri Mar 03 06:44:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
    2017-03-03 mashirong

相关资讯

国内“近视ICL专科门诊”正式成立

2017年1月8日,“近视ICL专科门诊”在复旦大学附属眼耳鼻喉科医院正式成立。作为STAAR Surgical公司举办的2017“ICL高峰论坛”上的一个重要环节,周行涛教授、王晓瑛教授、沈晔教授、刘磊教授、杨亚波教授、邓应平教授、余克明教授等七位近视矫正专家共同见证了这一历史时刻。

全球知名制药公司联合成立全新行业标准小组

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

张强医生集团临床中心全面落户北京善方医院

本次合作双方已经达成,张强医生集团将在北京善方医院落地静脉病中心、面部轮廓整形中心等,张强医生同时表示,根据张强医生集团逐步发展,我们会将更多的北京地区的临床中心落户到善方医院。

聚焦齿科3D打印技术,TCT亚洲展2017强势登沪

20多年来,TCT一直代表着3D科技革命的前沿;从早期的快速成型开始,TCT就已成为3D打印、增材制造和产品开发技术跨终端用户、企业和工业应用的重要信息来源和资讯“宝典”。

TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂

®(通用名:盐酸苯达莫司汀)已在日本获得批准,作为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤(MCL)的一线抗癌剂。 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:

2016“医药卫生界生命英雄”推选结果揭晓

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_